Table 1

Summary of prospective and retrospective studies of treatment with novel agents for primary plasma cells leukemia.

References	Study design	Patients, N	Median age, yr (range)	ORR/CR (%)	ASCT, N	Median PFS (mo)	Median OS (mo)
Musto et al. [24]	Prospective	23	60 (44–80)	73.9/13	9	14	28
Royer et al. [23]	Prospective	39	57 (27–71)	69/10	25	15.1	36.3
Nandakumar et al. [25]	Retrospective	68	62 (34–91)	90/47	20	13	23
Dhakal et al. [30]	Retrospective	277	60 (25–77)	87/19	277	17% at 4 yr	28% at 4 yr
Mina et al. [31]	Retrospective	38	58 (34–80)	82/18	28	20	33
Gowda et al. [32]	Retrospective	23	56 (42–71)	65/13	23	5.5	18.1
D’Arena et al. [22]	Retrospective	29	62 (42–82)	79/28	12	40% at 2 yr	55% at 2 yr